SELLAS Life Sciences (SLS) Reports Preliminary Data Showing Clinical Benefit from Phase 1/2 Clinical Trial of Galinpepimut-S (GPS) in Combination with Keytruda

SELLAS Reports Preliminary Data Showing Clinical Benefit from Phase 1/2 Clinical Trial of Galinpepimut-S (GPS) in Combination with Keytruda® in Patients with WT1+ Advanced Ovarian Cancer

- Overall Response Rate of 7.7 percent is similar to checkpoint inhibitors alone -

- Disease Control Rate for GPS combination (GPS plus Keytruda) is 53.9 percent compared to 37.2 percent in a checkpoint inhibitor single agent study in a similar patient population treated with checkpoint inhibitor alone -

- Median Progression Free Survival for GPS combination (GPS plus Keytruda) is 12 weeks compared to 8.4 weeks in a checkpoint inhibitor single agent study in a similar patient population treated with checkpoint inhibitor alone -

- Median Overall... More